1210344-83-4
Chemical Structure
Ertugliflozin L-pyroglutamic acid
Synonym(s): PF-04971729 L-pyroglutamic acid
- CAS No.: 1210344-83-4
- Formula:C27H32ClNO10
- Molecular Weight:566.00
IUPAC Name: (S)-5-oxopyrrolidine-2-carboxylic acid compound with (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol (1:1)
InChIKey: YHIUPZFKHZTLSH-LXYIGGQGSA-N
SMILES: ClC1=CC=C([C@]23O[C@@](CO)(CO3)[C@@H](O)[C@H](O)[C@H]2O)C=C1CC4=CC=C(OCC)C=C4.O=C5CC[C@@H](C(O)=O)N5
Biological Activity: Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2[1]. Has the potential for the treatment of type 2 diabetes mellitus[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ertugliflozin L-pyroglutamic acid | 99.80% | Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.83
HY-15461Ertugliflozin -
Similarity Score 0.74
HY-168989Olorigliflozin -
Similarity Score 0.73
HY-123011Henagliflozin -
Similarity Score 0.72
HY-15461SErtugliflozin-d5 -
Similarity Score 0.68
HY-101782HSK0935 -
Similarity Score 0.65
HY-42373R(2S,3R,4S,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol (Standard) -
Similarity Score 0.64
HY-128723Dapagliflozin impurity -
Similarity Score 0.64
HY-Z0048R1-C-[4-Chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucopyranose (Standard) -
Similarity Score 0.62
HY-138944SGLT1/2-IN-1 -
Explore the MedChemAI to find more analogs
References
- [1]. Mascitti V, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem. 2011 Apr 28;54(8):2952-60. [Content Brief]
- [2]. Miao Z, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013 Feb;41(2):445-56. [Content Brief]